Department of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Department of Medical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
BMC Cancer. 2018 Feb 13;18(1):176. doi: 10.1186/s12885-018-4092-4.
The clinical utility and prognostic impact of presumed primary breast or ovarian cancer among patients with an unfavorable subset of cancer of unknown primary site (CUP) remains unclear. We aimed to evaluate the clinical relevance of the presumed primary site of CUP and the clinical outcome of site-specific therapy based on such presumptions.
Patients referred to our center who were diagnosed with unfavorable-subset CUP and treated between April 2007 and March 2015 were enrolled in this study. Data were collected retrospectively from the hospital database and electronic medical records. Presumptive primary breast or ovarian cancer was based on histological and immunohistochemical analyses and metastatic patterns. The outcomes of patients with unfavorable-subset CUP with a putative primary site in the breast or ovary (P-CUP) and of patients with unfavorable-subset CUP, but without P-CUP (U-CUP), were assessed.
A total of 780 patients were referred to our hospital with malignancy of unknown origin. Of these, 409 patients were diagnosed with CUP and 344 patients with unfavorable-subset CUP. Following clinicopathological examination, 40 (11.6%) of the 344 patients had P-CUP and the remaining 303 (88.3%) patients had U-CUP. In total, 136 patients received chemotherapy (22 with P-CUP and 114 with U-CUP). Among the 22 patients with P-CUP, three received hormonal therapy for breast cancer, and 19 received chemotherapy based on the presumed primary organ (breast, 4; ovaries, 15). Conventional platinum-based chemotherapy was administered to 105 patients with U-CUP and non-platinum drug treatment to nine patients. The objective response rates were 61.1% (95% confidence interval [CI]: 38.6-83.6) and 41.1% (95% CI: 31.8-50.4) for patients with P-CUP and U-CUP, respectively. The median overall survival durations were 50.0 months and 16.9 months (log-rank: P = 0.002) for patients with P-CUP and U-CUP, respectively. P-CUP was identified as an independent predictor of good prognosis according to multivariate analysis.
Patients with P-CUP had higher response rates and a better prognosis compared with patients with U-CUP. It might thus be reasonable to classify this subset as a new category of CUP with a favorable prognosis.
对于癌症原发灶不明(CUP)中具有不利亚组的患者,假定的原发性乳腺癌或卵巢癌的临床效用和预后影响仍不清楚。我们旨在评估 CUP 中假定的原发部位的临床相关性以及基于这些假定的特定部位治疗的临床结果。
本研究纳入了 2007 年 4 月至 2015 年 3 月间我院收治的具有不利亚组 CUP 并接受治疗的患者。数据从医院数据库和电子病历中回顾性收集。假定的原发性乳腺癌或卵巢癌是基于组织学和免疫组织化学分析以及转移模式得出的。评估了具有假定的原发性乳腺癌或卵巢癌(P-CUP)的不利亚组 CUP 患者和没有 P-CUP 的不利亚组 CUP(U-CUP)患者的结局。
共有 780 名患者因恶性肿瘤就诊,来源不明。其中,409 名患者被诊断为 CUP,344 名患者为不利亚组 CUP。经过临床病理检查,344 名患者中有 40 名(11.6%)为 P-CUP,其余 303 名(88.3%)为 U-CUP。共有 136 名患者接受了化疗(22 名 P-CUP,114 名 U-CUP)。在 22 名 P-CUP 患者中,3 名接受了乳腺癌激素治疗,19 名接受了假定原发器官(乳腺,4 例;卵巢,15 例)的化疗。105 名 U-CUP 患者接受了常规铂类化疗,9 名患者接受了非铂类药物治疗。P-CUP 和 U-CUP 患者的客观缓解率分别为 61.1%(95%置信区间[CI]:38.6-83.6)和 41.1%(95% CI:31.8-50.4)。P-CUP 和 U-CUP 患者的中位总生存期分别为 50.0 个月和 16.9 个月(对数秩检验:P=0.002)。多因素分析显示,P-CUP 是预后良好的独立预测因素。
与 U-CUP 患者相比,P-CUP 患者的反应率更高,预后更好。因此,将这一亚组分类为具有良好预后的 CUP 新类别可能是合理的。